Skip to main content

Table 1 Characteristics of randomized clinical trials included in study

From: Infection risks in multiple myeloma: a systematic review and meta-analysis of randomized trials from 2015 to 2019

Author (Year)

Trial Name

Study Phase

Phase Treatment

Regimen

No. Patients

Median Age (Years)

Median Duration of Treatment (Months)

Niesvizky (2015) [14]

UPFRONT

3

ND

Bortezomib/dexamethasone

165

74.5

6

    

Bortezomib/thalidomide/dexamethasone

158

73

4.6

    

Bortezomib/melphalan/prednisone

163

72

4.7

Richardson (2015) [33]

 

2

RR

Elotuzumab/lenalidomide/dexamethasone

73

62

19.1

Mateos (2019) [15]

ALCYONE

3

ND

Daratumumab/bortezomib/melphalan/prednisone

346

71

13.5

Voorhees (2019) [16]

GRIFFIN

2

ND

Daratumumab/lenalidomide/bortezomib/dexamethasone

99

59

22.1

Usmani (2019) [38]

KEYNOTE-185

3

RR

Pembrolizumab/lenalidomide/dexamethasone

149

74

4.4

Mateos (2019) [40]

COLUMBA

3

RR

Subcutaneous daratumumab

260

65

7.5

    

IV daratumumab

258

68

7.5

Spicka (2019) [34]

ADMYRE

3

RR

Plitidepsin/dexamethasone

167

64

3

Rosinol (2019) [17]

PETHEMA/GEM2012

3

ND

Bortezomib/lenalidomide/dexamethasone prior to transplant

458

58

6

Attal (2019) [35]

ICARIA-MM

3

RR

Isatuximab/pomalidomide/dexamethasone

152

68

10.2

Morgan (2019) [41]

TOURMALINE-MM3 study

3

M

Ixazomib maintenance

395

58

15.2

Moreau (2019) [36]

BELLINI

3

RR

Venetoclax/bortezomib/dexamethasone

194

66

18.7

Moreau (2019) [18]

CASSIOPEIA

3

ND

Daratumumab/bortezomib/melphalan/prednisone prior to and following transplant

536

59

8.9

Richardson (2019) [27]

OPTISIMISMM

3

RR

Bortezomib/pomalidomide/dexamethasone

278

67

8.8

Mateos (2019) [26]

KEYNOTE-183

3

RR

Pembrolizumab/pomalidomide/dexamethasone

120

65

4.1

Dimopoulos (2018) [30]

POLLUX

3

RR

Daratumumab/lenalidomide/dexamethasone

283

65

24.5

Jackson (2019) [24]

Myeloma XI

3

ND

Cyclophosphamide/bortezomib/dexamethasone induction

275

66

2.8

Horvath (2019) [19]

VCAT

3

ND

Bortezomib/thalidomide/prednisolone consolidation

103

58

10.2

Facon (2019) [23]

CLARION

3

ND

Carfilzomib/melphalan/prednisone

474

72

13.1

Facon (2019) [20]

MAIA

3

ND

Daratumumab/lenalidomide/dexamethasone

364

73

25.3

Lonial (2015) [25]

ELOQUENT-2

3

RR

Elotuzumab/lenalidomide/dexamethasone

318

67

17

Dimopoulos (2016) [37]

ENDEAVOR

3

RR

Carfilzomib

463

65

10

Spencer (2018) [31]

CASTOR

3

RR

Daratumumab/bortezomib/dexamethasone

243

64

13.4

Moreau (2018) [28]

A.R.R.O.W.

3

RR

Once weekly carfilzomib

238

66

9.5

    

Twice weekly carfilzomib

235

66

7.3

Dimopoulos (2018) [29]

ELOQUENT-3

2

RR

Elotuzumab/pomalidomide/dexamethasone

60

69

8.4

Hajek (2016) [32]

FOCUS

3

RR

Carfilzomib

157

63

4.1

Durie (2017) [21]

SWOG S0777

3

ND

Bortezomib/lenalidomide/dexamethasone non-transplant

242

63

5.6

Bringhen (2019) [42]

EMN01

3

M

Lenalidomide maintenance

204

73

32.4

    

Lenalidomide/prednisone maintenance

198

73

29.8

Zweegman (2016) [43]

HOVON-NSMG

3

M

Thalidomide maintenance

121

72

5

    

Lenalidomide maintenance

124

73

17

Moreau (2016) [39]

 

3

RR

Ixazomib/lenalidomide/dexamethasone

361

66

15.9

Jacobus (2016) [22]

E1A05

3

NF

Bortezomib/lenalidomide/dexamethasone consolidation,

23

 

4.55

Gay (2015) [44]

 

3

M

Lenalidomide maintenance

117

57

28.9

    

lenalidomide/prednisone maintenance

106

56

25.3